Evopoint's New Gout Drug XNW3009 Enrolled the First Patient in its Phase III Clinical Trial

On February 8, 2024, Evopoint Biosciences Co., Ltd. (hereinafter referred to as “Evopoint”) announced that the first patient had been enrolled in the Phase III clinical trial of XNW3009, its core pipeline product for the treatment of gout. In two previously completed randomized, double-blind, controlled trials, XNW3009 demonstrated significantly superior uric acid-lowering efficacy compared to both Benzbromarone and Febuxostat, the two most prescribed and highest-selling drugs on the market. Compared to Febuxostat, XNW3009 achieved a uric acid target rate of up to 90%, while the control group achieved 74%. Moreover, XNW3009 was well tolerated. As Febuxostat will also be used as the control group in this Phase III trial, even better clinical data is anticipated.

Mr. Le Meijie, Co-founder and CEO of Evopoint, expressed, “The enrollment of the first patient in the Phase III registration clinical trial of XNW3009 marks another important milestone in Evopoint’s new drug development and represents another positive sign for gout patients seeking alternative uric acid-lowering therapies. Evopoint’s team will continue to work tirelessly to accelerate the clinical development and commercialization of this new generation of uric acid-lowering drugs in China. We anticipate with great confidence that this key clinical study will end up successful, enabling XNW3009 to benefit a large number of gout patients at an early date.”